Printer Friendly

MAGAININ PHARMACEUTICALS INITIATES PIVOTAL PHASE IIb/III CLINICAL TRIALS FOR MSI-78

 PLYMOUTH MEETING, Pa., June 30 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced that its broad spectrum topical anti-infective, MSI-78, has entered the first of the anticipated two pivotal clinical trials for the treatment of impetigo. The objective of this Phase IIb/III trial is to compare the safety and effectiveness of three concentrations of MSI-78 topical cream to a control vehicle. The trial is being supervised by clinicians associated with the University of Miami School of Medicine and is expected to enroll 280 patients. It is being conducted in Puerto Rico, where the incidence of impetigo, a serious skin infection usually occurring in children, is high.
 The successful results achieved in a previously completed Phase II study of MSI-78 has led to an accelerated initiation of this pivotal study. The results of the earlier study have been submitted for presentation at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in the fall.
 "It is our plan to develop MSI-78 for a variety of serious skin infections," said Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals Inc. "If our impetigo studies are successful, it will indicate MSI-78's effectiveness against gram positive organisms, such as those that cause impetigo. Later, we hope to begin other studies to assess MSI-78's effectiveness against gram negative and fungal organisms."
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti- infectives and anti-cancer products based upon compounds isolated from the host defense systems of animals.
 -0- 6/30/93
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals Inc., 215-941-4020; or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals Inc./
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:

SM-LR -- NY004 -- 7002 06/30/93 08:38 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:293
Previous Article:IBM MULTIMEDIA STUDIO TO PUBLISH PLAYBOY INTERVIEWS ON COMPACT DISC
Next Article:HUNTCO ANNOUNCES PUBLIC OFFERING OF COMMON STOCK
Topics:


Related Articles
MAGAININ'S LEAD DRUG CANDIDATE TO ENTER PIVOTAL PHASE IIB/III CLINICAL TRIALS
MAGAININ PHARMACEUTICALS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Magainin Announces Successful MSI-78 Phase III Trial Results
Isis Receives $10 Million Milestone Payment from Boehringer Ingelheim for Isis 2302
Magainin Announces Successful Results of Second Pivotal Trial For Cytolex (MSI-78)
Neurocrine Biosciences Announces Expansion of NBI-6024 Clinical Program to the United States.
Neurocrine Biosciences and Taisho Pharmaceutical Initiate A Pivotal Phase IIb Clinical Trial for NBI-6024, A Therapeutic Vaccine for the Treatment of...
Renovis Receives Milestone Payment From Astrazeneca As Phase III Trials Of Cerovive(R) (Nxy-059) Commence; Company Expands Management Team.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters